Health News Releases

  • Today May 2
January 11, 2024 09:45
Medidata Secures Top Honors in Everest Group’s Decentralized Clinical Trial Platforms PEAK Matrix® Assessment
Medidata (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.medidata.com%2Fen%2F&esheet=53879943&newsitemid=20240110694798&lan=en-US&anchor=Medidata&index=1&md5=f2d573b2db328d38013
Kolmar BNH confirmed dual functionality of HemoHIM for immune enhancement and fatigue improvement
January 10, 2024 16:22
Kolmar BNH’s HemoHIM gets dual recognition for fatigue improvement, immune enhancement
Kolmar BNH, a Korean health supplement original development manufacturing (ODM), said the Ministry of Food and Drug Safety has recognized both fatigue improvement and immune enhancement capabilities f
Example of HistoSonics technology targeting kidney tissue to be destroyed in a non-invasive histotri
January 10, 2024 15:10
World’s First Kidney Tumor Treated Using the HistoSonics’ Edison® Histotripsy System
HistoSonics, Inc., (www.histosonics.com), developer of a non-invasive platform and novel sonic beam therapy called histotripsy, announced today the treatment of the first patient in its pivotal #HOPE4
“The NEUROFUSE Study has yielded promising early clinical results consistent with preclinical studie
January 10, 2024 13:20
Neuraptive Therapeutics, Inc. Announces Achievement of Proof of Concept in The NEUROFUSE Study of NTX-001 for the Adjunct Treatment of Transected Peripheral Nerves
Neuraptive Therapeutics, Inc., a leader in nerve repair and regeneration, is pleased to announce a significant milestone in transforming the treatment paradigm for peripheral nerve injuries. The succe
January 10, 2024 10:10
Biocytogen Enters into Bispecific Antibody Drug Conjugate Agreement with Radiance Biopharma
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315), a global biotech company focusing on the discovery of novel antibody therapeutics, today announces that it has entered into
(Photo: Business Wire)
January 09, 2024 15:15
ENYO Pharma Announces a €39 Million Series C Financing and FDA Clearance to Advance Vonafexor in a Phase 2 Clinical Trial for Patients With Alport Syndrome
ENYO Pharma (“ENYO”) announced that it has received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to initiate a Phase 2 clinical study of
January 09, 2024 14:00
Validant Group of Companies Unite as ELIQUENT Life Sciences
The Validant Group of companies today announced a strategic repositioning that unites the five companies as one global regulatory brand: ELIQUENT Life Sciences. ELIQUENT Life Sciences is the fusion
HistoSonics Edison Histotripsy System (Photo: Business Wire)
January 07, 2024 12:54
World’s First Patients Treated With Novel Edison® Histotripsy System
HistoSonics, (www.histosonics.com), the manufacturer of the non-invasive Edison® Histotripsy System, announced today a patient from the University of Rochester Medical Center has received the world’s
January 07, 2024 11:23
Kenvue to Announce Fourth Quarter and Full Year 2023 Results on February 8, 2024
Kenvue Inc. (NYSE: KVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, will announce its financial results for the fourth quarter and full year ending December 31, 2023
January 05, 2024 11:15
ReNAgade to Present at the Upcoming 42nd Annual J.P. Morgan Healthcare Conference
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that Amit D. Munshi, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthca
January 05, 2024 10:30
Merck Expands Colorectal Cancer Portfolio Through Licensing Agreement with Inspirna
Merck, a leading science and technology company, today announced a licensing agreement with Inspirna, Inc. (New York, NY) for ompenaclid (RGX-202), a first-in-class oral inhibitor of the creatine tran
December 29, 2023 09:30
Fujirebio Expands Its Alzheimer’s Disease Test Menu With the Much Awaited and Fully Automated Lumipulse® G pTau 217 Plasma Assay for Research Use Only (RUO)
H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G pTau 217 Plasma assay for the fully automated LUMIPULSE G immunoassay systems. Th
December 28, 2023 14:30
CCM Biosciences Announces Launch of 5Prime Sciences Business Unit
Diversified biotechnology company CCM Biosciences (CCM Bio) announced the launch of its business unit CCM 5Prime Sciences (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fccm-bio.com
December 22, 2023 13:59
Takeda Announces China NMPA Approval of LIVTENCITY® (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Refractory to Prior Therapies
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=53874021&newsitemid=20231221976317&lan=en-US&anchor=TSE%3A4
December 21, 2023 10:15
Biocytogen Enters into Multi-Target Antibody Agreement With Neurocrine Biosciences
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announced that it has entered into an antibody evaluation and option agreement with Neurocrine Biosciences, Inc. The ag
December 20, 2023 11:25
Organon & Lilly Enter Commercialization Agreement in Europe for Two Migraine Medicines
Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, announced an agreement with Eli Lilly and Company (Lilly) to become the sole distributor and promoter for the migraine
December 19, 2023 13:50
DENTALIS Animal Health Awarded with VOHC Seal
Dentalis Animal Health, dedicated to the development of superior oral health care products for companion animals, proudly announces its first Veterinary Oral Health Council (VOHC) approval. Dentalis'
December 19, 2023 10:45
Biocytogen Enters into Antibody Agreement with Ona Therapeutics to Develop Antibody-Drug Conjugates Targeting Solid Tumors
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315), a global biotech company focusing on the discovery and development of novel antibody therapeutics, today announces an antibo
On December 1st, 2023, the Memorandum of Understanding (MOU) signing ceremony for Lydia AI's Korean
December 19, 2023 09:40
Lydia AI Expands Reach in Korea Through Strategic Partnerships with Hecto Data and Tobecon
Lydia AI, a leading Canadian health AI company, is thrilled to announce its strategic collaborations with Hecto Data and Tobecon Inc., two prominent technology companies in South Korea. These partners
December 17, 2023 10:50
Takeda Receives Positive CHMP Opinion for HYQVIA® as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&esheet=53870362&newsitemid=20231213527272&lan=en-US&anchor=TSE%3A4502%2FNYSE%
QPS Netherlands High Resolution Mass Spectrometry Laboratory in Groningen, The Netherlands. (Photo:
December 15, 2023 15:20
QPS Continues UPLC-HRMS Expansion Into Europe to Support Gene Therapy and Protein Drug Development
QPS Holdings, LLC (QPS), a global contract research organization (CRO) that provides discovery, preclinical, bioanalysis, clinical trials, and clinical research services, is reinforcing its focus on q
December 15, 2023 14:50
Parse Biosciences Closes $50 Million of Financing to Fuel Continued Worldwide Growth
Parse Biosciences (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.parsebiosciences.com%2F&esheet=53870688&newsitemid=20231214617151&lan=en-US&anchor=Parse+Biosciences&index=1&md
December 15, 2023 10:40
Fujirebio and Sysmex Sign Agreement for the Supply of Reagent Raw Materials in the Field of Immunoassay
Fujirebio Holdings, Inc. (President & CEO: Goki Ishikawa) and Sysmex Corporation (President: Kaoru Asano) today announced that they have signed an agreement for the mutual supply of reagent raw materi
WHOOP announces its “Year In Review” celebrating that 2023 was the year human performance became a l
December 14, 2023 13:20
WHOOP Announces Its “Year In Review” Celebrating That 2023 Was the Year Human Performance Became a Lifestyle
WHOOP (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.whoop.com%2F&esheet=53869622&newsitemid=20231211786571&lan=en-US&anchor=WHOOP&index=1&md5=fa89e2d87172001de9758c69dd9680af)
Martin Steinhart, CEO, AOP Health; Copyright: AOP Health/Studio Koekart
December 14, 2023 12:10
AOP Health Receives Market Authorization for Landiolol in Canada
At the end of November 2023, AOP Orphan Pharmaceuticals GmbH (AOP Health), an Austrian pharmaceutical company based in Vienna, received authorization from the Canadian Health Authority (Health Canada)
25 per page50 per page75 per page100 per page